Heart Failure with Etanercept Therapy: A Case Report

Ma, Khan; Dorm,; Neyses, Ludwig; Ma, Mamas

doi:10.4172/2155-9880.1000236

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several systemic antipsoriatic drugs, including retinoids and cyclosporine, may predispose patients to cardiovascular diseases (Corbetta, Angioni, Cattaneo, Beck-Peccoz, & Spada, 2006). Tumor necrosis factor α inhibitors are associated with a risk of exacerbating heart failure, and measurement of NT-proBNP may be useful to follow-up the psoriatic patients who receive these drugs (Khan, Dormand, Neyses, & Mamas, 2013). Furthermore, in our study, serum NT-proBNP level was positively correlated with total cholesterol and low-density lipoprotein levels in the psoriatic patients.…”

Section: Psoriasis Nt-probnp Cardiovascularsupporting

confidence: 49%

Can serum level of N‐terminal pro B‐type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease?

Shahidi‐Dadras

Niknezhad

Niknejad

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Past studies have reported associations between psoriasis, metabolic syndrome, and atherosclerotic cardiovascular disease. According to studies, N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) is a useful screening test for cardiac disease. We examined the serum NT‐proBNP level in patients with psoriasis and compared them with nonpsoriatic healthy control subjects. Sixty‐one patients with psoriasis were enrolled, along with 61 age, sex, and body mass index (BMI) matched control subjects. In both groups, NT‐proBNP serum levels and lipid profile parameters were investigated. Means and 95% confidence intervals (CIs) were reported. The median serum concentration of NT‐proBNP was higher in psoriatic patients than the control group (26.67 [interquartile range (IQR): 15.15–43.03 and range: 5–250] vs. 17.45 [IQR: 12.35–20.80 and range: 5–45.09, p < 0.0001). NT‐proBNP serum level in psoriatic arthritis patients (11%; 55.6 ± 25.7 pg/mL, 95% CI: 31.9–79.4 pg/mL) was higher than psoriasis patients without arthritis (35.8 ± 40.6 pg/mL, CI: 24.7–46.9, p < 0.001). NT‐proBNP levels were also positively correlated with BMI, lipid profile, and disease duration. NT‐proBNP is elevated in patients with psoriasis, consistent with the high risk of cardiovascular disease associated with psoriasis.

show abstract

Section: Psoriasis Nt-probnp Cardiovascularsupporting

confidence: 49%

Can serum level of N‐terminal pro B‐type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease?

Shahidi‐Dadras

Niknezhad

Niknejad

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Indeed, increased TNF levels are seen in patients with LVH and other cardiac disorders 49 50 51 52 53 54 55 . However, results from large clinical trials, as well as several case reports, suggest that too much TNF inhibition can lead to dilated cardiomyopathy and/or heart failure 56 57 58 59 . Notably, cardiac function is preserved in our TNF antibody-treated mice.…”

Section: Discussionmentioning

confidence: 99%

Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome

et al. 2017

View full text Add to dashboard Cite

Noonan syndrome (NS) is caused by mutations in RAS/ERK pathway genes, and is characterized by craniofacial, growth, cognitive and cardiac defects. NS patients with kinase-activating RAF1 alleles typically develop pathological left ventricular hypertrophy (LVH), which is reproduced in Raf1L613V/+ knock-in mice. Here, using inducible Raf1L613V expression, we show that LVH results from the interplay of cardiac cell types. Cardiomyocyte Raf1L613V enhances Ca2+ sensitivity and cardiac contractility without causing hypertrophy. Raf1L613V expression in cardiomyocytes or activated fibroblasts exacerbates pressure overload-evoked fibrosis. Endothelial/endocardial (EC) Raf1L613V causes cardiac hypertrophy without affecting contractility. Co-culture and neutralizing antibody experiments reveal a cytokine (TNF/IL6) hierarchy in Raf1L613V-expressing ECs that drives cardiomyocyte hypertrophy in vitro. Furthermore, postnatal TNF inhibition normalizes the increased wall thickness and cardiomyocyte hypertrophy in vivo. We conclude that NS-cardiomyopathy involves cardiomyocytes, ECs and fibroblasts, TNF/IL6 signalling components represent potential therapeutic targets, and abnormal EC signalling might contribute to other forms of LVH.

show abstract

Changes of MicroRNA-1, -15b and -21 Levels in Irradiated Rat Hearts After Treatment With Potentially Radioprotective Drugs

Kura

Yin²,

Frimmel³

et al. 2016

Physiol Res

View full text Add to dashboard Cite

The aim of this study was to measure expression levels of microRNAs (miRNAs) (miRNA-1, -15b and -21) in the rat myocardium after a single dose of ionizing radiation (6-7 Gy/min, total 25 Gy). The rats were treated with selected drugs (Atorvastatin, acetylsalicylic acid (ASA), Tadalafil, Enbrel) for six weeks after irradiation. MiRNAs levels were measured by RT-qPCR. Irradiation down-regulated miRNA-1 in irradiated hearts. In Tadalafil- and Atorvastatin-treated groups, miRNA-1 expression levels were further decreased compared with irradiated controls. However, Enbrel increased miRNA-1 level in irradiated hearts similarly to that in non-irradiated untreated group. Increase of miRNA-15b is pro-apoptotic in relationship with ischemia. Irradiation caused down-regulation of miRNA-15b. Administration of ASA in the irradiated group resulted in the increase of miRNA-15b expression compared to non-treated controls without irradiation. After Enbrel administration, miRNA-15b levels were overexpressed compared to non-treated normal group. MiRNA-21 belongs to the most markedly up-regulated miRNAs in response to cardiogenic stress. MiRNA-21 was increased nearly 2-fold compared to non-treated hearts whereas Tadalafil reduced miRNA-21 levels (about 40 %). Our study suggests that Enbrel and Tadalafil changed miRNAs expression values of the irradiated rats to the values of non-irradiated controls, thus they might be helpful in mitigation of radiation-induced toxicity.

show abstract

Heart Failure with Etanercept Therapy: A Case Report

Cited by 3 publications

References 16 publications

Can serum level of N‐terminal pro B‐type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease?

Can serum level of N‐terminal pro B‐type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease?

Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome

Changes of MicroRNA-1, -15b and -21 Levels in Irradiated Rat Hearts After Treatment With Potentially Radioprotective Drugs

Contact Info

Product

Resources

About